NEW YORK, NY / ACCESSWIRE / October 13, 2017 / Major Indexes pulled back on Thursday as investors digested earnings from JPMorgan Chase and Citigroup. The Dow Jones Industrial Average declined 0.14 percent to close at 22,841.01, while the S&P 500 Index fell 0.17 percent to close at 2,550.93. The Nasdaq Composite Index decreased 0.18 percent to close at 6,591.51. On Thursday, earnings from Citigroup and JPMorgan Chase signaled the start of earnings season.
"Basic fundamentals are good, companies are making money, and I think the market will be relatively strong throughout earnings season, but I don't see a huge spike up between now and the end of the year because a lot [of earnings optimism] has been priced in," said Gary Droz, managing director at MainLine Private Wealth.
RDI Initiates Coverage on:
Halozyme Therapeutics Inc.'s (NASDAQ: HALO) stock moved 4.04% higher Thursday, to close the day at $17.78. The stock recorded a trading volume of 1,841,883 shares, which was above its three months average volume of 1,216,100 shares. In the last year, Halozyme Therapeutics Inc.'s shares have traded in a range of 8.18 - 17.92. The share price has gained 117.36% from its 52-week low. The company's shares are currently trading above their 200-day moving average. Moreover, the stock's 50-day moving average of $15.18 is greater than its 200-day moving average of $13.68. Shares of Halozyme Therapeutics have gained approximately 79.96 percent year-to-date.
Access RDI's Halozyme Therapeutics Inc. Research Report at: https://rdinvesting.com/news/?ticker=HALO
On Thursday, shares in Akers Biosciences Inc. (NASDAQ: AKER) recorded a trading volume of 5,560,297 shares, which was above the three months average volume of 74,323 shares. The stock ended the day 46.24% higher at 1.26. The share price has gained 80.21% from its 52-week low with a 52-week trading range of 0.70 - 3.60.The company's shares are currently trading at their 200-day moving average. Moreover, the stock's 50-day moving average of $0.92 is below its 200-day moving average of $1.26. Shares of Akers Biosciences have fallen approximately 33.68 percent year-to-date.
Access RDI's Akers Biosciences Inc. Research Report at: https://rdinvesting.com/news/?ticker=AKER
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.